{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948870",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948870_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"adalimumab\" outputclass=\"int-drug\">adalimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  adalimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Adalimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948871",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948871_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"aldesleukin\" outputclass=\"int-drug\">aldesleukin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  aldesleukin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Aldesleukin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948872",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948872_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"alemtuzumab\" outputclass=\"int-drug\">alemtuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  alemtuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Alemtuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948873",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948873_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"amsacrine\" outputclass=\"int-drug\">amsacrine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  amsacrine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Amsacrine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948874",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948874_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"arsenic trioxide\" outputclass=\"int-drug\">arsenic trioxide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  arsenic trioxide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Arsenic trioxide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948875",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948875_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"asparaginase\" outputclass=\"int-drug\">asparaginase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  asparaginase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Asparaginase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948876",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948876_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"axitinib\" outputclass=\"int-drug\">axitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  axitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Axitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948877",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948877_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"azacitidine\" outputclass=\"int-drug\">azacitidine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  azacitidine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azacitidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948878",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948878_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"azathioprine\" outputclass=\"int-drug\">azathioprine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  azathioprine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Azathioprine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948879",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948879_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"Bacillus Calmette-GuÃ©rin vaccine\" outputclass=\"int-drug\">Bacillus Calmette-GuÃ©rin vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bacillus Calmette-GuÃ©rin vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bacillus Calmette-GuÃ©rin vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948880",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948880_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"belatacept\" outputclass=\"int-drug\">belatacept</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  belatacept  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Belatacept</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948881",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948881_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"bevacizumab\" outputclass=\"int-drug\">bevacizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  bevacizumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bevacizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948882",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948882_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"bexarotene\" outputclass=\"int-drug\">bexarotene</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  bexarotene  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bexarotene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948883",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948883_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  bleomycin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948883_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"bleomycin\" outputclass=\"int-drug\">bleomycin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  bleomycin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bleomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948884",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948884_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"blinatumomab\" outputclass=\"int-drug\">blinatumomab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  blinatumomab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Blinatumomab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948885",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948885_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"bortezomib\" outputclass=\"int-drug\">bortezomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  bortezomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bortezomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948886",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948886_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"bosutinib\" outputclass=\"int-drug\">bosutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  bosutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948887",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948887_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"brentuximab vedotin\" outputclass=\"int-drug\">brentuximab vedotin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  brentuximab vedotin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Brentuximab vedotin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948888",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948888_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"cabazitaxel\" outputclass=\"int-drug\">cabazitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  cabazitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabazitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948889",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948889_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"cabozantinib\" outputclass=\"int-drug\">cabozantinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  cabozantinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cabozantinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948890",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948890_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"canakinumab\" outputclass=\"int-drug\">canakinumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  canakinumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Canakinumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948891",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948891_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"capecitabine\" outputclass=\"int-drug\">capecitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  capecitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Capecitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948892",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948892_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"carboplatin\" outputclass=\"int-drug\">carboplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  carboplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carboplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948893",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948893_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"carfilzomib\" outputclass=\"int-drug\">carfilzomib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  carfilzomib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carfilzomib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948894",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948894_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ceritinib\" outputclass=\"int-drug\">ceritinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ceritinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ceritinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948895",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948895_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"certolizumab pegol\" outputclass=\"int-drug\">certolizumab pegol</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  certolizumab pegol  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Certolizumab pegol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948896",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948896_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"cisplatin\" outputclass=\"int-drug\">cisplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  cisplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cisplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948897",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948897_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"cladribine\" outputclass=\"int-drug\">cladribine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  cladribine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cladribine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948898",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948898_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"clofarabine\" outputclass=\"int-drug\">clofarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  clofarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clofarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948899",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948899_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"crisantaspase\" outputclass=\"int-drug\">crisantaspase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  crisantaspase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Crisantaspase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948900",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948900_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"cytarabine\" outputclass=\"int-drug\">cytarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  cytarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cytarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948901",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948901_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"dactinomycin\" outputclass=\"int-drug\">dactinomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  dactinomycin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dactinomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948902",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948902_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"daratumumab\" outputclass=\"int-drug\">daratumumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  daratumumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daratumumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948903",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948903_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"darbepoetin alfa\" outputclass=\"int-drug\">darbepoetin alfa</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  darbepoetin alfa  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Darbepoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948904",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948904_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"dasatinib\" outputclass=\"int-drug\">dasatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  dasatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dasatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948905",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948905_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"daunorubicin\" outputclass=\"int-drug\">daunorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  daunorubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Daunorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948906",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948906_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"decitabine\" outputclass=\"int-drug\">decitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  decitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Decitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948907",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948907_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"dexrazoxane\" outputclass=\"int-drug\">dexrazoxane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  dexrazoxane  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexrazoxane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948908",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948908_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"dinutuximab\" outputclass=\"int-drug\">dinutuximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  dinutuximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dinutuximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948909",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948909_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"docetaxel\" outputclass=\"int-drug\">docetaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  docetaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Docetaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948910",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948910_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  doxorubicin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948910_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"doxorubicin\" outputclass=\"int-drug\">doxorubicin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  doxorubicin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Doxorubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948911",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948911_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"epirubicin\" outputclass=\"int-drug\">epirubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  epirubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epirubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948912",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948912_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"epoetin alfa\" outputclass=\"int-drug\">epoetin alfa</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  epoetin alfa  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948913",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948913_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"epoetin beta\" outputclass=\"int-drug\">epoetin beta</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  epoetin beta  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948914",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948914_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"epoetin zeta\" outputclass=\"int-drug\">epoetin zeta</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  epoetin zeta  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Epoetin zeta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948915",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948915_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"eribulin\" outputclass=\"int-drug\">eribulin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  eribulin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eribulin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948916",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948916_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"etoposide\" outputclass=\"int-drug\">etoposide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  etoposide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etoposide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948917",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948917_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"fludarabine\" outputclass=\"int-drug\">fludarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  fludarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fludarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948918",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948918_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  fluorouracil  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948918_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"fluorouracil\" outputclass=\"int-drug\">fluorouracil</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  fluorouracil  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "49",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluorouracil</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948919",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948919_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"fulvestrant\" outputclass=\"int-drug\">fulvestrant</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  fulvestrant  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "50",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fulvestrant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948920",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948920_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ganciclovir\" outputclass=\"int-drug\">ganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "51",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948921",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948921_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"gemcitabine\" outputclass=\"int-drug\">gemcitabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  gemcitabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "52",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemcitabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948922",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948922_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"gemtuzumab ozogamicin\" outputclass=\"int-drug\">gemtuzumab ozogamicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  gemtuzumab ozogamicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "53",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gemtuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948923",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948923_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"golimumab\" outputclass=\"int-drug\">golimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  golimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "54",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Golimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948924",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948924_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"herpes-zoster vaccine, live\" outputclass=\"int-drug\">Herpes-zoster vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Herpes-zoster vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "55",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Herpes-zoster vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948925",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948925_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"hydroxycarbamide\" outputclass=\"int-drug\">hydroxycarbamide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  hydroxycarbamide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "56",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hydroxycarbamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948926",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948926_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ibrutinib\" outputclass=\"int-drug\">ibrutinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ibrutinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "57",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ibrutinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948927",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948927_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"idarubicin\" outputclass=\"int-drug\">idarubicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  idarubicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "58",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Idarubicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948928",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948928_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  imatinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "59",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948929",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948929_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"infliximab\" outputclass=\"int-drug\">infliximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  infliximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "60",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Infliximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948930",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948930_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"influenza vaccine (live)\" outputclass=\"int-drug\">Influenza vaccine (live)</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Influenza vaccine (live)   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "61",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Influenza vaccine (live)</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948931",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948931_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"inotuzumab ozogamicin\" outputclass=\"int-drug\">inotuzumab ozogamicin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  inotuzumab ozogamicin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "62",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Inotuzumab ozogamicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948932",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948932_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ipilimumab\" outputclass=\"int-drug\">ipilimumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ipilimumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "63",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ipilimumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948933",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948933_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"irinotecan\" outputclass=\"int-drug\">irinotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  irinotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "64",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Irinotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948934",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948934_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"isavuconazole\" outputclass=\"int-drug\">Isavuconazole</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Isavuconazole   is predicted to   increase   the exposure to   cyclophosphamide .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "65",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isavuconazole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948935",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948935_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"leflunomide\" outputclass=\"int-drug\">leflunomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  leflunomide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "66",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Leflunomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948936",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948936_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  lenalidomide  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948936_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"lenalidomide\" outputclass=\"int-drug\">lenalidomide</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  lenalidomide  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "67",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lenalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948937",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948937_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"measles, mumps and rubella vaccine, live\" outputclass=\"int-drug\">Measles, mumps and rubella vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Measles, mumps and rubella vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "68",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Measles, mumps and rubella vaccine, live</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948938",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948938_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"mercaptopurine\" outputclass=\"int-drug\">mercaptopurine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  mercaptopurine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "69",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mercaptopurine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948939",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948939_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  methotrexate  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948939_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"methotrexate\" outputclass=\"int-drug\">methotrexate</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  methotrexate  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "70",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methotrexate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948940",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948940_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"methoxy polyethylene glycol-epoetin beta\" outputclass=\"int-drug\">methoxy polyethylene glycol-epoetin beta</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  methoxy polyethylene glycol-epoetin beta  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "71",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methoxy polyethylene glycol-epoetin beta</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948941",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948941_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"mifamurtide\" outputclass=\"int-drug\">mifamurtide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  mifamurtide  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "72",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mifamurtide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948942",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948942_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  mitomycin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948942_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"mitomycin\" outputclass=\"int-drug\">mitomycin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  mitomycin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "73",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitomycin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948943",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948943_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"mitotane\" outputclass=\"int-drug\">mitotane</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  mitotane  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "74",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948944",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948944_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"mitoxantrone\" outputclass=\"int-drug\">mitoxantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  mitoxantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "75",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitoxantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948945",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948945_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"mogamulizumab\" outputclass=\"int-drug\">mogamulizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  mogamulizumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "76",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mogamulizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948946",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948946_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"nelarabine\" outputclass=\"int-drug\">nelarabine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  nelarabine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "77",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nelarabine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948947",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948947_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"netupitant\" outputclass=\"int-drug\">Netupitant</ph> <ph outputclass=\"int-magnitude\">very slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor for toxicity</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Netupitant   very slightly   increases   the exposure to   cyclophosphamide .  Manufacturer advises monitor for toxicity .    \n\n"
						}
					],
					"hasOrder": "78",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Netupitant</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948948",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948948_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"nilotinib\" outputclass=\"int-drug\">nilotinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  nilotinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "79",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nilotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948949",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948949_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"niraparib\" outputclass=\"int-drug\">niraparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  niraparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "80",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Niraparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948950",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948950_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"nivolumab\" outputclass=\"int-drug\">nivolumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  nivolumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "81",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nivolumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948951",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948951_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"obinutuzumab\" outputclass=\"int-drug\">obinutuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  obinutuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "82",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Obinutuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948952",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948952_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"olaparib\" outputclass=\"int-drug\">olaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  olaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "83",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Olaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948953",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948953_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"oxaliplatin\" outputclass=\"int-drug\">oxaliplatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  oxaliplatin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "84",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxaliplatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948954",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948954_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"paclitaxel\" outputclass=\"int-drug\">paclitaxel</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  paclitaxel  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "85",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paclitaxel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948955",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948955_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"palbociclib\" outputclass=\"int-drug\">palbociclib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  palbociclib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "86",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palbociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948956",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948956_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"panobinostat\" outputclass=\"int-drug\">panobinostat</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  panobinostat  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "87",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Panobinostat</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948957",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948957_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pegaspargase\" outputclass=\"int-drug\">pegaspargase</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  pegaspargase  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "88",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pegaspargase</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948958",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948958_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"peginterferon alfa\" outputclass=\"int-drug\">peginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  peginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "89",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Peginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948959",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948959_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pembrolizumab\" outputclass=\"int-drug\">pembrolizumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  pembrolizumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "90",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pembrolizumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948960",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948960_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pemetrexed\" outputclass=\"int-drug\">pemetrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  pemetrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "91",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemetrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948961",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948961_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"pemigatinib\" outputclass=\"int-drug\">Pemigatinib</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to the active metabolite of</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Pemigatinib   might   increase   the exposure to the active metabolite of   cyclophosphamide .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "92",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pemigatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948962",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948962_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  pentostatin  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948962_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  pentostatin  can increase the risk of thromboembolism. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948962_message_2",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">Cyclophosphamide</ph> <ph outputclass=\"int-substanceQualifier\">(high-dose)</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of toxicity when given with</ph> <ph otherprops=\"pentostatin\" outputclass=\"int-drug\">pentostatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "3",
							"hasTextContent": "Cyclophosphamide   (high-dose)   increases   the risk of toxicity when given with   pentostatin .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "93",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentostatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948963",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948963_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pixantrone\" outputclass=\"int-drug\">pixantrone</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  pixantrone  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "94",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pixantrone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948964",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948964_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  pomalidomide  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948964_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"pomalidomide\" outputclass=\"int-drug\">pomalidomide</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  pomalidomide  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "95",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pomalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948965",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948965_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  procarbazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "96",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948966",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948966_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"raloxifene\" outputclass=\"int-drug\">raloxifene</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  raloxifene  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "97",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raloxifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948967",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948967_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"raltitrexed\" outputclass=\"int-drug\">raltitrexed</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  raltitrexed  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "98",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Raltitrexed</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948968",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948968_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ramucirumab\" outputclass=\"int-drug\">ramucirumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ramucirumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "99",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ramucirumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948969",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948969_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"regorafenib\" outputclass=\"int-drug\">regorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  regorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "100",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Regorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948970",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948970_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ribociclib\" outputclass=\"int-drug\">ribociclib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ribociclib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "101",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ribociclib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948971",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948971_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"rituximab\" outputclass=\"int-drug\">rituximab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  rituximab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "102",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rituximab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948972",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948972_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ropeginterferon alfa\" outputclass=\"int-drug\">ropeginterferon alfa</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ropeginterferon alfa  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "103",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ropeginterferon alfa</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948973",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948973_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rotavirus vaccine\" outputclass=\"int-drug\">Rotavirus vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rotavirus vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "104",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rotavirus vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948974",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948974_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"rucaparib\" outputclass=\"int-drug\">rucaparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  rucaparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "105",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rucaparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948975",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948975_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"ruxolitinib\" outputclass=\"int-drug\">ruxolitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  ruxolitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "106",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ruxolitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948976",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948976_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  sorafenib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "107",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948977",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948977_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"streptozocin\" outputclass=\"int-drug\">streptozocin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  streptozocin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "108",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Streptozocin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948978",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948978_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"strontium\" outputclass=\"int-drug\">strontium</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  strontium  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "109",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Strontium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948979",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948979_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"sulfasalazine\" outputclass=\"int-drug\">sulfasalazine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  sulfasalazine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "110",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sulfasalazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948980",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948980_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"sunitinib\" outputclass=\"int-drug\">sunitinib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  sunitinib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "111",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sunitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948981",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948981_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">Cyclophosphamide</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the risk of prolonged neuromuscular blockade when given with</ph> <ph otherprops=\"suxamethonium\" outputclass=\"int-drug\">suxamethonium</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Cyclophosphamide   increases   the risk of prolonged neuromuscular blockade when given with   suxamethonium .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "112",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Suxamethonium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948982",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948982_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"talazoparib\" outputclass=\"int-drug\">talazoparib</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  talazoparib  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "113",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Talazoparib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948983",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948983_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"tamoxifen\" outputclass=\"int-drug\">tamoxifen</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  tamoxifen  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "114",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tamoxifen</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948984",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948984_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"tegafur\" outputclass=\"int-drug\">tegafur</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  tegafur  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "115",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tegafur</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948985",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948985_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"temsirolimus\" outputclass=\"int-drug\">temsirolimus</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  temsirolimus  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "116",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Temsirolimus</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948986",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948986_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  thalidomide  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948986_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"thalidomide\" outputclass=\"int-drug\">thalidomide</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  thalidomide  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "117",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Thalidomide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948987",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948987_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"tibolone\" outputclass=\"int-drug\">tibolone</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  tibolone  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "118",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tibolone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948988",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948988_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"tioguanine\" outputclass=\"int-drug\">tioguanine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  tioguanine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "119",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tioguanine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948989",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948989_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"topotecan\" outputclass=\"int-drug\">topotecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  topotecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "120",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Topotecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948990",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948990_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"toremifene\" outputclass=\"int-drug\">toremifene</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  toremifene  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "121",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Toremifene</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948991",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948991_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"trabectedin\" outputclass=\"int-drug\">trabectedin</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  trabectedin  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "122",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trabectedin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948992",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948992_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"tranexamic acid\" outputclass=\"int-drug\">tranexamic acid</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  tranexamic acid  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "123",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranexamic acid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948993",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948993_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"trastuzumab\" outputclass=\"int-drug\">trastuzumab</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  trastuzumab  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "124",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948994",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948994_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"trastuzumab deruxtecan\" outputclass=\"int-drug\">trastuzumab deruxtecan</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  trastuzumab deruxtecan  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "125",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab deruxtecan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948995",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948995_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"trastuzumab emtansine\" outputclass=\"int-drug\">trastuzumab emtansine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  trastuzumab emtansine  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "126",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trastuzumab emtansine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948996",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948996_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"tretinoin\" outputclass=\"int-drug\">tretinoin</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  tretinoin  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "127",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tretinoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948997",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948997_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"typhoid vaccine, oral\" outputclass=\"int-drug\">Typhoid vaccine, oral</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Typhoid vaccine, oral   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "128",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Typhoid vaccine, oral</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948998",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948998_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"valganciclovir\" outputclass=\"int-drug\">valganciclovir</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  valganciclovir  can increase the risk of myelosuppression. \n\n"
						}
					],
					"hasOrder": "129",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Valganciclovir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948999",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857948999_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"varicella-zoster vaccine\" outputclass=\"int-drug\">Varicella-zoster vaccine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Varicella-zoster vaccine   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "130",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Varicella-zoster vaccine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949000",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949000_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  vinblastine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949000_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vinblastine\" outputclass=\"int-drug\">vinblastine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  vinblastine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "131",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinblastine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949001",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949001_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  vincristine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949001_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vincristine\" outputclass=\"int-drug\">vincristine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  vincristine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "132",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vincristine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949002",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949002_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  vindesine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949002_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vindesine\" outputclass=\"int-drug\">vindesine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  vindesine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "133",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vindesine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949003",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949003_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  vinflunine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949003_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vinflunine\" outputclass=\"int-drug\">vinflunine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  vinflunine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "134",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinflunine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949004",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949004_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of myelosuppression.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  cyclophosphamide  and  vinorelbine  can increase the risk of myelosuppression. \n\n"
						},
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949004_message_1",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph> and <ph otherprops=\"vinorelbine\" outputclass=\"int-drug\">vinorelbine</ph> can increase the risk of thromboembolism.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "2",
							"hasTextContent": "Both  cyclophosphamide  and  vinorelbine  can increase the risk of thromboembolism. \n\n"
						}
					],
					"hasOrder": "135",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vinorelbine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949005",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2#bnf_i1643857949005_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"yellow fever vaccine, live\" outputclass=\"int-drug\">Yellow fever vaccine, live</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of generalised infection (possibly life-threatening) when given with</ph> <ph otherprops=\"cyclophosphamide\" outputclass=\"int-heading-drug\">cyclophosphamide</ph>. <ph outputclass=\"int-action\">UKHSA advises avoid (refer to Green Book)</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Yellow fever vaccine, live   is predicted to   increase   the risk of generalised infection (possibly life-threatening) when given with   cyclophosphamide .  UKHSA advises avoid (refer to Green Book) .    \n\n"
						}
					],
					"hasOrder": "136",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Yellow fever vaccine, live</title>"
					}
				}
			],
			"hasSearchLabel": " Cyclophosphamide  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/cyclophosphamide-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Cyclophosphamide </title>"
			},
			"rdfs:label": "cyclophosphamide"
		}
	]
}